Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Myeloproliferative neoplasms in Mexico: An analysis of clinical features, driver mutations, and disease progression patterns in a case series.

View Full Paper
Ask AI
Bookmark
Share

Authors

KUKatya Unzueta-VillalobosDRDiana Romero-Terrazas

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals high thrombosis rates in myeloproliferative neoplasms, indicating the need for tailored management strategies.

Key Points

  • Thrombosis prevalence was notably high: 50.0% in primary myelofibrosis and 25.0% in Essential Thrombocythemia.
  • The analysis included 63 adult patients, with the mean age at diagnosis being 59.9 years.
  • Retrospective case series across three medical centers revealed significant discrepancies with international literature.
  • Findings suggest a need for intensified surveillance and personalized management of myeloproliferative neoplasms in the Mexican population.

Cite This Study

Unzueta-Villalobos et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4fbhttps://doi.org/10.1182/blood-2025-7328
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinicopathological characteristics and outcome of patients with Philadelphia negative myeloproliferative neoplasms: first report from Upper Egypt2025
  2. 2Epidemiology and outcomes of patients with myeloproliferative neoplasms in the United States: A SEER database analysis, years 2000-20212025
  3. 3Clinical features and outcomes of myelofibrosis patients with MPL mutations2025
  4. 4Clinical characteristics, disease progression, and vascular events in essential thrombocythemia: A single-center cohort study with long-term follow-up.2025
  5. 5Myeloproliferative neoplasms-unclassifiable (MPN-U): A carefully curated series of 30 Mayo Clinic patients2025